Express News | Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BreakingsJun 5 04:10

Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive

BusinesswireMay 30 20:00

Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final STAR-0215 Phase 1a

BusinesswireMay 24 20:00

Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present two posters at the

BusinesswireMay 23 20:00

Astria Therapeutics Is Maintained at Outperform by Oppenheimer

Astria Therapeutics Is Maintained at Outperform by Oppenheimer

Dow JonesMay 21 20:12

Oppenheimer: The Astria Therapeutics (ATXS.US) rating was maintained, and the target price was adjusted from better than market to better than market, and the target price was adjusted from $29.00 to $25.00.

Oppenheimer: The Astria Therapeutics (ATXS.US) rating was maintained, and the target price was adjusted from better than market to better than market, and the target price was adjusted from $29.00 to $25.00.

Zhitong FinanceMay 21 20:03